J&J predicts faster coronavirus vaccine sales amid debate over boosters

Bio Pharma Dive

billion in sales from its shot this year, despite concerns over protection against variants and significant manufacturing setbacks The pharmaceutical company expects $2.5

Sales 247

Sales manager

Pharma Phorum

Create and disseminate sales support materials. Manage and develop sales team (sales manager role only). Proven experience of working as part of a sales team. Proven work experience working in a sales-based role. The post Sales manager appeared first on.

Sales 83
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna vaccine sales surpass expectations as company looks to fall boosters

Bio Pharma Dive

The trajectory of COVID-19 vaccine sales is now harder to predict amid questions about the rollout of additional doses and whether purchasing in the U.S.

Sales 229

Gilead sales propped up by COVID-19 drug Veklury

Bio Pharma Dive

Sales of the antiviral drug accounted for a quarter of the biotech's product revenue in the fourth quarter, disguising hits to its business elsewhere

Sales 247

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Bio Pharma Dive

Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations. But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness

After setbacks, a gene therapy company mulls a sale

Bio Pharma Dive

Sio Gene Therapies, formerly known as Axovant, said it's focused on conserving cash, and has decided to significantly reduce its workforce and terminate licensing agreements on its last two pipeline programs

Biogen's Alzheimer's drug sales remain slow as company warns of further cost cuts

Bio Pharma Dive

Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage

Sales 229

Seagen shares sink as sales outlook of cancer drug disappoint

Bio Pharma Dive

The biotech is predicting sales of Tukysa, its new breast cancer drug, will remain flat or fall in 2022 as competition increases from AstraZeneca's rival medicine Enhertu

Sales 158

Esperion lays off nearly half its workforce as heart drug sales disappoint

Bio Pharma Dive

The company hopes a "streamlined" sales force can turn around a drug launch that's failed to meet expectations amid tough competition from rival medicines

Sales 236

Argenx drug succeeds in trial, beats sales forecasts

Bio Pharma Dive

The biotech reported positive results from a study meant to expand Vyvgart's use to another immune disorder, while sales from the drug's first quarter on the market exceeded expectations

Sales 130

Merck sees up to $7B in coming sales of coronavirus pill

Bio Pharma Dive

But sales could climb even higher if it works as a preventive treatment too Executives based their projections on contracts already in place for the drug, known as molnupiravir.

Sales 254

Eversana aims athletes’ mental coaching at pharma sales reps

Pharma Phorum

Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. Digital News Sales and Marketing digital Sales reps Training

Sales 96

Merck, GSK vaccine sales hit by pandemic as competitors' business booms

Bio Pharma Dive

Both companies blamed the impact of COVID-19 on sharp declines in sales of their shingles, pneumonia and HPV shots

Sales 251

Pfizer forecasts $100B in sales, fueled by COVID-19 vaccine, pill

Bio Pharma Dive

The company estimated revenue from its COVID-19 vaccine and antiviral pill Paxlovid will total $54 billion this year. Curiously, its stock fell by more than 5

Sales 229

Pfizer forecasts $15B sales boost from coronavirus vaccine orders

Bio Pharma Dive

The estimate for 2021 sales, which Pfizer splits with partner BioNTech, would make the vaccine one of the highest-selling medicines in the industry

Sales 193

Pfizer sales of COVID-19 vaccine climb, with tens of billions more expected next year

Bio Pharma Dive

The drugmaker again increased its forecast for 2021 sales, this time to $36 billion, or about 80% of what the rest of Pfizer's business is expected to earn this year

Sales 229

Vaccine sales driven down by pandemic's effects on doctor visits

Bio Pharma Dive

Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations

Biohaven beats expectations with fast sales of migraine drug

Bio Pharma Dive

Second quarter sales of Nurtec ODT, which recently became the first migraine drug cleared for acute and preventive treatment, were nearly twice what analysts on Wall Street had predicted

Sales 164

Amgen expects rising sales through 2030, but Wall Street still has doubts

Bio Pharma Dive

Facing falling sales of top-seller Enbrel, the biotech tried to shore up confidence in its ability to grow new products, like the cancer drug Lumakras

Sales 158

Sales coaching: preparing for the new reality in pharma

Pharma Phorum

COVID-19 has been a catalyst for a huge amount of change across the pharmaceutical industry, acting as an accelerant for progress in its use of digital technology and prompting a reassessment of how the sales function should work. The industry faces the dawn of a new age in sales coaching.

Sales 82

Biogen and its partner rework terms of Aduhelm deal amid slow sales

Bio Pharma Dive

Instead of sharing global profits and losses, Eisai will receive royalties tied to net sales of the Alzheimer's drug. Biogen, meanwhile, said the amended deal should make it easier to "address market developments "

Sales 151

Pfizer pledges not-for-profit sale of medicines in low-income countries

Bio Pharma Dive

The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally. The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries

Sales 206

New study reports need to monitor public interest in shopping and sales of popular Puff Bar e-cigarette brand

Scienmag

ATLANTA, May 12, 2022 – New research led by scientists at the American Cancer Society (ACS) shows the need for continued surveillance of the changes in shopping interest and sales for Puff Bar, the most preferred brand of electronic cigarettes or e-cigarettes among youth in the United States.

Novartis expects sales lift from expanded heart drug approval

Bio Pharma Dive

The Swiss drugmaker's pill Entresto is now cleared in the U.S. for use in patients with stronger hearts, expanding the eligible population by two-thirds

Sales 231

Cloudbyz & Salesforce: Sales Enablement Workshop

Cloudbyz

Tuesday, March 22nd Cloudbyz joined Salesforce at their Chicago offices for a joint sales enablement event discussing both the clinical trial space and how Salesforce and Cloudbyz solutions help life science organizations get their products to market faster.

Sales 52

Acceleron provides biggest biopharma deal this year, with $11.5B sale to Merck

Bio Pharma Dive

The acquisition is notable for Merck, which is under pressure to diversify its business beyond the cancer drug Keytruda and has typically favored smaller buyouts

Sales 274

GSK beats forecasts, thanks to COVID antibody and Shingrix sales

Pharma Phorum

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. billion with no sales recorded in the prior year. News Sales and Marketing GlaxoSmithKline Shingrix xevudy

Sales 82

How COVID-19 has changed the role of pharma sales reps

Pharma Phorum

The demise of the pharmaceutical sales representative has been greatly exaggerated over the years. The current restrictions on face-to-face meetings have exacerbated the trend of sales reps’ reduced access to healthcare customers.

Sales 94

What Employers Really Look For in Medical Sales Candidates

BioSpace

BioSpace spoke with Jay Johnson, the Director of Talent Acquisition for Orthopedics at Stryker, to find out what it takes to land a job in medical sales

Sales 82

Moderna cuts vaccine sales, delivery targets for 2021

Bio Pharma Dive

The biotech now expects to deliver between 700 million and 800 million doses this year, down from a previous forecast of 800 million to 1 billion

Sales 164

Biohaven migraine drug sales again top Wall Street forecasts

Bio Pharma Dive

The neuroscience-focused biotech continues to win market share in a battle with some of the industry's largest companies

Sales 169

Novartis to consider sale or separation of Sandoz business

Bio Pharma Dive

The generic drug unit has struggled in recent years, while Novartis has moved to focus more narrowly on higher-margin branded medicines

J&J foresees end to not-for-profit sales of coronavirus vaccine

Bio Pharma Dive

The drugmaker plans to switch over to a commercial business model late next year or early in 2023, said Jennifer Taubert, head of J&J's pharma division

Sales 254

Sandoz bulks up ahead of possible sale with Coalesce buy

Pharma Phorum

Analysts have suggested its financial troubles could make a sale more difficult, as could untangling Sandoz from Novartis’ broader manufacturing operations, although the launch of new biosimilars next year could help lift margins.

Sales 86

DarshanTalks: Sales & Marketing Oversight – April 21, 2021

Pharma Marketing Network

The Pharma Marketing Podcast is pleased to present this special guest episode from our friend and Editorial Advisory Board member Darshan Kulkarni, Sales and Marketing Oversight – April 21, 2021. [link].

Sales 77

GSK gets £1.4bn sales lift from COVID-19 products in 2021

Pharma Phorum

There was another £447 million from sales of GSK’s adjuvant, used to boost the efficacy of other companies’ COVID-19 shots, although the company’s own efforts to develop a jab have so far been unsuccessful. Last year, sales at the JV stabilised at £9.6

Sales 87

No news anytime soon on Sandoz sale, says Novartis

Pharma Phorum

Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit may not come until the last quarter of the year.

Sales 83

J&J cuts COVID vaccine sales forecasts, citing high supplies and lagging demand

Bio Pharma Dive

The drugmaker previously expected up to $3.5 billion in 2022 revenue, but uncertainty about the pace of vaccinations led it to suspend investor guidance

Sales 164

BridgeBio sale of FDA voucher good news for Bluebird, other biotech sellers

Bio Pharma Dive

The drugmaker was able to get $110 million for its voucher, a kind of regulatory fast pass. Other vouchers have sold for similar amounts, boding well for Bluebird, which plans to sell two that it hopes to get this year

Sales 151

Storytelling is a secret weapon for increasing service sales and overcoming employee resistance to change

Scienmag

Social & Behavioral Science change employee Increasing Overcoming resistance sales secret Service storytelling weaponWith the increasing digitalization in manufacturing industries, companies start to integrate big data analytics into business processes and sell smart services.

Sales 83

Bayer triples sales forecast for prostate cancer drug Nubeqa

Pharma Phorum

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours.

Sales 83

Regeneron tries to shake off fall in COVID drug sales with first quarter earnings

Bio Pharma Dive

Partnerships and profit-sharing deals helped Regeneron overcome the sudden loss of U.S. revenue for its coronavirus antibody, which was withdrawn from the market as omicron spread